Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Shares Issued (2023 - 2025)

Historic Shares Issued for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $5.6 million.

  • NewAmsterdam Pharma's Shares Issued changed N/A to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 2893.23%. This contributed to the annual value of $13.8 million for FY2024, which is 5960.33% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Shares Issued stood at $5.6 million.
  • Over the past 5 years, NewAmsterdam Pharma's Shares Issued peaked at $8.8 million during Q1 2024, and registered a low of $1000.0 during Q3 2023.
  • Over the past 3 years, NewAmsterdam Pharma's median Shares Issued value was $4.7 million (recorded in 2024), while the average stood at $4.4 million.
  • In the last 5 years, NewAmsterdam Pharma's Shares Issued skyrocketed by 26634.62% in 2024 and then plummeted by 2649.21% in 2025.
  • NewAmsterdam Pharma's Shares Issued (Quarter) stood at $1000.0 in 2023, then skyrocketed by 33900.0% to $340000.0 in 2024, then surged by 1552.35% to $5.6 million in 2025.
  • Its Shares Issued stands at $5.6 million for Q3 2025, versus $3.4 million for Q2 2025 and $7.9 million for Q1 2025.